JP7200238B2 - グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針 - Google Patents

グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針 Download PDF

Info

Publication number
JP7200238B2
JP7200238B2 JP2020519850A JP2020519850A JP7200238B2 JP 7200238 B2 JP7200238 B2 JP 7200238B2 JP 2020519850 A JP2020519850 A JP 2020519850A JP 2020519850 A JP2020519850 A JP 2020519850A JP 7200238 B2 JP7200238 B2 JP 7200238B2
Authority
JP
Japan
Prior art keywords
glp
analogue
pharmaceutical composition
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523420A (ja
JP2020523420A5 (https=
Inventor
ソンネ，キム
モウリツェン，ウルリーク
グレルプ，ペーター
イェッペセン，パレ・ベッケル
Original Assignee
ジーランド・ファルマ・アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62748940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7200238(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1709643.9A external-priority patent/GB201709643D0/en
Priority claimed from GBGB1714203.5A external-priority patent/GB201714203D0/en
Priority claimed from GBGB1800873.0A external-priority patent/GB201800873D0/en
Application filed by ジーランド・ファルマ・アー／エス filed Critical ジーランド・ファルマ・アー／エス
Publication of JP2020523420A publication Critical patent/JP2020523420A/ja
Publication of JP2020523420A5 publication Critical patent/JP2020523420A5/ja
Priority to JP2022203265A priority Critical patent/JP7566859B2/ja
Application granted granted Critical
Publication of JP7200238B2 publication Critical patent/JP7200238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020519850A 2017-06-16 2018-06-15 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針 Active JP7200238B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022203265A JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1709643.9 2017-06-16
GBGB1709643.9A GB201709643D0 (en) 2017-06-16 2017-06-16 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
GB1714203.5 2017-09-05
GBGB1714203.5A GB201714203D0 (en) 2017-09-05 2017-09-05 Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues
GB1800873.0 2018-01-19
GBGB1800873.0A GB201800873D0 (en) 2018-01-19 2018-01-19 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
PCT/EP2018/065951 WO2018229252A1 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022203265A Division JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Publications (3)

Publication Number Publication Date
JP2020523420A JP2020523420A (ja) 2020-08-06
JP2020523420A5 JP2020523420A5 (https=) 2021-07-26
JP7200238B2 true JP7200238B2 (ja) 2023-01-06

Family

ID=62748940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020519850A Active JP7200238B2 (ja) 2017-06-16 2018-06-15 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針
JP2022203265A Active JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022203265A Active JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Country Status (19)

Country Link
US (3) US20200000883A1 (https=)
EP (3) EP4424362A3 (https=)
JP (2) JP7200238B2 (https=)
KR (2) KR102754148B1 (https=)
CN (2) CN111032072A (https=)
AU (2) AU2018285580B2 (https=)
BR (1) BR112019026711A2 (https=)
CA (1) CA3066523A1 (https=)
CL (1) CL2019003660A1 (https=)
CO (1) CO2019014028A2 (https=)
DK (2) DK3638291T3 (https=)
ES (2) ES2894629T3 (https=)
IL (2) IL299864B2 (https=)
MX (2) MX2019015054A (https=)
PE (1) PE20200678A1 (https=)
SG (1) SG11201912161SA (https=)
TW (1) TWI791539B (https=)
WO (1) WO2018229252A1 (https=)
ZA (2) ZA201908355B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN111560061A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Gelpaglutide的制备方法
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
MX2023006901A (es) 2020-12-16 2023-06-26 Zealand Pharma As Uso de analogos de glp-2 en pacientes con insuficiencia renal.
RS67423B1 (sr) 2021-09-10 2025-12-31 Zealand Pharma As Postupak za formulisanje sastava koji sadrže analoge glukagonu sličnog peptida-2 (glp-2)
IL313732A (en) 2021-12-23 2024-08-01 Zealand Pharma As Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
WO2023132609A1 (ko) * 2022-01-05 2023-07-13 주식회사 휴온스랩 지속형 지방산-펩타이드 유도체 및 이의 용도
US20250186555A1 (en) * 2022-02-24 2025-06-12 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-2
KR20250075601A (ko) 2022-09-30 2025-05-28 질랜드 파마 에이/에스 글루카곤-유사-펩타이드-2(glp-2) 유사체 및 단장 증후군(sbs) 치료를 위한 이의 의학적 용도
IL322328A (en) 2023-01-27 2025-09-01 Zealand Pharma As Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS)
CN116478269A (zh) * 2023-04-28 2023-07-25 成都奥达生物科技有限公司 一种长效替度鲁肽化合物
TW202535919A (zh) 2023-12-28 2025-09-16 丹麥商西蘭製藥公司 類升糖素肽2(glp-2)類似物之調配物及其用途
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518941A (ja) 2004-11-01 2008-06-05 エヌピーエス アレリックス コーポレーション 大腸連続性を伴う短腸症候群患者の治療
JP2008539713A (ja) 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DE69740176D1 (de) 1996-03-01 2011-05-26 Novo Nordisk As Appetithemmendes Peptid, Zusammensetzung und Verwendung
EP1231219B1 (en) 1996-04-12 2010-08-25 1149336 Ontario Inc. GLucagon-like peptide-2 analogs
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CA2289652C (en) 1997-05-16 2012-02-28 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
EP2583675A1 (en) 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU7421598A (en) 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2020501A (en) 1999-12-08 2001-06-18 1149336 Ontario Inc. Chemotherapy treatment
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP1970072A1 (en) 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
RU2329823C2 (ru) 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
BR122019021416A2 (https=) 2003-09-19 2019-12-21
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US20050256036A1 (en) 2004-01-27 2005-11-17 Boyle Bryan J Gastrointestinal proliferative factor and uses thereof
WO2005082404A2 (en) 2004-02-27 2005-09-09 Novo Nordisk A/S Glp-2 derivatives modified by lipophilic substituents
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
CN101331224A (zh) * 2005-10-24 2008-12-24 森托科尔公司 Glp-2模拟体、多肽、组合物、方法和用途
CN101341254A (zh) 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
CN101668535B (zh) 2006-12-29 2017-07-28 益普生制药股份有限公司 Glp‑1药物组合物
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
CN101824087A (zh) 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
KR20130115086A (ko) 2010-05-17 2013-10-21 세빅스 인코포레이티드 페길화된 c-펩티드
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
CN102212127B (zh) 2011-05-17 2015-02-04 上海景泽生物技术有限公司 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途
DK2710031T3 (en) 2011-05-18 2018-01-02 Mederis Diabetes Llc IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
JP6206972B2 (ja) * 2011-09-12 2017-10-04 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
IN2015DN00544A (https=) 2012-07-23 2015-06-26 Zealand Pharma As
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
WO2016065181A1 (en) 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
CN107257681A (zh) 2014-12-23 2017-10-17 卡姆拉斯公司 控释配制品
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
WO2017053822A1 (en) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Detected object tracker for a video analytics system
LT3541366T (lt) 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018142363A1 (en) 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
GB201710822D0 (en) 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
US20190275110A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CA3129576A1 (en) * 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518941A (ja) 2004-11-01 2008-06-05 エヌピーエス アレリックス コーポレーション 大腸連続性を伴う短腸症候群患者の治療
JP2008539713A (ja) 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLoS ONE，2012年，7(11): e50630，doi:10.1371/journal.pone.0050630

Also Published As

Publication number Publication date
CL2019003660A1 (es) 2020-05-04
TW201904607A (zh) 2019-02-01
IL271245A (en) 2020-01-30
EP3881861A1 (en) 2021-09-22
DK3638291T3 (da) 2021-10-18
ZA201908355B (en) 2024-06-26
RU2019142586A (ru) 2021-07-16
WO2018229252A1 (en) 2018-12-20
TWI791539B (zh) 2023-02-11
MX2023003828A (es) 2023-04-13
ES2894629T3 (es) 2022-02-15
IL299864B1 (en) 2024-02-01
JP2020523420A (ja) 2020-08-06
KR20230035677A (ko) 2023-03-14
DK3881861T3 (da) 2024-09-09
KR20200020817A (ko) 2020-02-26
IL271245B1 (en) 2023-06-01
US12297251B1 (en) 2025-05-13
US20250136655A1 (en) 2025-05-01
IL271245B2 (en) 2023-10-01
EP3881861B1 (en) 2024-07-31
ES2989204T3 (es) 2024-11-25
AU2018285580B2 (en) 2024-05-09
US20200000883A1 (en) 2020-01-02
CN111032072A (zh) 2020-04-17
BR112019026711A2 (pt) 2020-06-30
EP3638291B1 (en) 2021-08-18
EP4424362A2 (en) 2024-09-04
JP2023036769A (ja) 2023-03-14
IL299864B2 (en) 2024-06-01
IL299864A (en) 2023-03-01
AU2018285580A1 (en) 2020-01-30
KR102754148B1 (ko) 2025-01-15
EP3638291A1 (en) 2020-04-22
PE20200678A1 (es) 2020-06-11
US20250136657A1 (en) 2025-05-01
JP7566859B2 (ja) 2024-10-15
AU2024202486A1 (en) 2024-06-27
MX2019015054A (es) 2020-02-13
SG11201912161SA (en) 2020-01-30
ZA202402068B (en) 2024-11-27
EP4424362A3 (en) 2024-11-27
KR102504200B1 (ko) 2023-02-28
CO2019014028A2 (es) 2020-04-01
AU2024202486B2 (en) 2024-07-18
CA3066523A1 (en) 2018-12-20
CN118526577A (zh) 2024-08-23

Similar Documents

Publication Publication Date Title
JP7566859B2 (ja) グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針
KR101200227B1 (ko) 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
RU2785662C9 (ru) Схемы дозирования для введения аналогов глюкагоноподобного пептида 2 (гпп-2)
RU2785662C2 (ru) Схемы дозирования для введения аналогов глюкагоноподобного пептида 2 (гпп-2)
CA3202157A1 (en) Use of glp-2 analogues in patients with renal insufficiency
HK40113969A (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40059738A (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40059738B (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40017010A (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40017010B (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221221

R150 Certificate of patent or registration of utility model

Ref document number: 7200238

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250